Publications

5674 Results

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

Authors
C Lao;V Ma;J Moon;J Fruehauf;L Flaherty;M Bury;W Martin;H Gross;W Akerley;J Hopkins;S Patel;V Sondak;A Ribas
Journal / Conference
Cancer Jan 1;131(1):e35587
Year
2025
Research Committee(s)
Melanoma
PMID
PMID39342463
PMC
PMC11694162
Study Number(s)
S0826

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Authors
R Banerjee;R Sexton;A Cowan;A Rosenberg;S Ailawadhi;V Rajkumar;S Kumar;S Lonial;B Durie;P Richardson;S Usmani;A Hoering;R Orlowski
Journal / Conference
Blood Jan 2;145(1):75-84
Year
2025
Research Committee(s)
Myeloma
PMID
PMID39321347
Study Number(s)
S0777, S1211

Neighborhood socioeconomic deprivation and patient-reported outcomes in symptom management trials for women with breast cancer

Authors
R Vaidya;C Till;NL Henry;M Fisch;D Hershman;J Unger
Journal / Conference
Breast Cancer Research and Treatment Feb;209(3):603-611
Year
2025
Research Committee(s)
Symptom Management and Survivorship
PMID
PMID39560823
Study Number(s)
S0927, S1200, S1202

Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants

Authors
C Presant;R Vaidya;C Till;K Ashing;G Warren;D Hershman;V Sun;R Salgia;E Massarelli;J Mortimer;G Idos;S Pal;T Dorff;A Amini;L Erhunmwunsee;T Phillips;A Johnson;B Adesunloye;F Bedell;A Tergas;I Amanam;S Rosen;J Unger
Journal / Conference
Cancer Jan 1;131(1):e35560
Year
2025
Research Committee(s)
Cancer Care Delivery
PMID
PMID39283236
PMC
PMC11834169

Intake and Nutritional Adequacy in Cancer Patients Diagnosed with Malignant Bowel Obstruction: A secondary analysis of a randomized trial

Authors
C Thomson;K Arnold;G Anderson;V Sun;A Secord;A Yung;M Al-Kaspooles;V Nfonsam;M Grant;G Deutsch;J Deneve;R Krouse
Journal / Conference
Journal of the Academy of Nutrition and Dietetics May;125(5):654-665.e3
Year
2025
Research Committee(s)
Palliative Care
PMID
PMID39603592
PMC
PMCIDPMC12009688
Study Number(s)
S1316

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vulvar Cancers

Authors
Y Chae;L Corthell;S Patel;R Edwards;J Scalici;H Kim;L Il-Young Chung;M Othus;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
Clinical Cancer Research Jan 17;31(2):308-315
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID39561273
PMC
PMC11804806
Study Number(s)
S1609

Correlation of body mass index with overall survival in patients with metastatic hormone-sensitive prostate cancer: Analysis of patient-level data from SWOG-1216 study

Authors
U Swami;Y Jo;A Narang;M Plets;C Chehade;G Gebrael;S Gupta;Z Myint;C Tangen;P Lara;I Thompson;M Hussain;T Dorff;S Lerner;N Agarwal
Journal / Conference
European Urology Oncology Jun;8(3):612-615
Year
2025
Research Committee(s)
Genitourinary
PMID
PMID39521639
PMC
PMC12059143
Study Number(s)
S1216

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (SWOG S1815; NCT#03768414)

Authors
R Shroff;G King;S Colby;A Scott;M Borad;K Matin;A Mahipal;A Kalyan;M Javle;I El Dika;B Tan;P Cheema;A Patel;R Iyer;R Kelley;J Thumar;A El-Khoueiry;K Guthrie;EG Chiorean;H Hochster;P Philip
Journal / Conference
Journal of Clinical Oncology Feb 10;43(5):536-544
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID39671534
PMC
PMC11798714
Study Number(s)
S1815

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive BC in the Phase III RxPONDER Trial (SWOG S1007)

Authors
Y Abdou;W Barlow;J Gralow;F Meric-Bernstam;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;S Dhesy-Thind;P Rastogi;E Alba;S Delaloge;A Schott;S Shak;P Sharma;D Lew;J Miao;J Unger;D Tripathy;L Pusztai;G Hortobagyi;K Kalinsky
Journal / Conference
JNCI-Journal of the National Cancer Institute May 1;117(5):889-897
Year
2025
Research Committee(s)
Breast
PMID
PMID39656951
PMC
PMC12058262
Study Number(s)
S1007

Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929

Authors
N Abdel Karim;J Miao;K Reckamp;C Gay;L Byers;Y Zhao;M Redman;D Carrizosa;W Wang;W Petty;K Mehta;B Faller;E Agamah;S Kasbari;R Malisetti;A Kumar;J Schallenkamp;K Alluri;J Gray;K Kelly
Journal / Conference
Journal of Thoracic Oncology Mar;20(3):383-394
Year
2025
Research Committee(s)
Lung
PMID
PMID39505259
Study Number(s)
S1929